4 days ago
Cantor Fitzgerald Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
In a report released yesterday, Rick Bienkowski from Cantor Fitzgerald reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target of $65.00. The company's shares closed yesterday at $7.45.
Confident Investing Starts Here:
Bienkowski covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Legend Biotech, and Verve Therapeutics. According to TipRanks, Bienkowski has an average return of -31.7% and a 6.67% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Intellia Therapeutics also received a Buy from JonesTrading's Debanjana Chatterjee in a report issued today. However, yesterday, Goldman Sachs maintained a Sell rating on Intellia Therapeutics (NASDAQ: NTLA).
Based on Intellia Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $16.63 million and a GAAP net loss of $114.33 million. In comparison, last year the company earned a revenue of $28.94 million and had a GAAP net loss of $107.44 million
